Mechanism of action study of anti-IL17 treatment in spondyloarthritis: Impact on cellular and molecular pathways of synovial inflammation and tissue remodeling.
Latest Information Update: 06 Nov 2021
Price :
$35 *
At a glance
- Drugs Secukinumab (Primary)
- Indications Spondylarthritis
- Focus Pharmacodynamics; Therapeutic Use
- 05 Jun 2018 Results published in the Arthritis and Rheumatology
- 17 Jun 2017 Results presented at the 18th Annual Congress of the European League Against Rheumatism
- 17 Jun 2017 Results presented at the 18th Annual Congress of the European League Against Rheumatism